A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

To be part of this study, you would need to be a man with prostate cancer that has spread, and your doctor must have confirmed this under a microscope. Your cancer should also be a type that has become resistant to hormone treatments, even though your male hormone levels are kept low, either by ongoing injections or if you've had surgery to remove your testicles. You will have already tried at least one other type of hormone therapy that targets the androgen receptor pathway, but no more than two, and you must have stopped taking it before joining the study.

There are also reasons why you might not be able to join. For example, if your prostate cancer has spread to your brain or the lining around your brain. Also, if you have certain genetic changes in the BRCA1 or BRCA2 genes, you might not be able to join unless you've already had a specific type of treatment (called a PARP inhibitor) or can't take it for medical reasons. If you've had another cancer that could affect how the study is measured, or if you've already had chemotherapy for your prostate cancer, you would likely not be able to participate. You also shouldn't have previously received treatments that specifically target human kallikrein 2 (KLK-2).

If you decide to take part in this study, you will receive either the investigational drug pasritamig along with docetaxel and prednisone, or docetaxel and prednisone alone. The study involves regular visits to the clinic for treatments, medical checks, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. These scans will help doctors see if your cancer is growing or staying stable. The duration of your participation will depend on how you respond to the treatment, or until your doctors decide it's no longer the best option for you. You will also have follow-up appointments after your treatment period ends.